Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 6/20 | 0.49 |
| ▸ | LPAR5 | Q9H1C0 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805739 | 0.94 | LPAR1 (0.43) | LPAR1LPAR5MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL6676692 | 0.91 | LPAR1 (0.59) | LPAR1LPAR5PTGES | |
| SCHEMBL6540487 | 0.90 | POLB (0.50) | MAPTMAPK1SMN1; SMN2POLBTP53 | |
| SCHEMBL6539924 | 0.90 | POLB (0.53) | MAPTMAPK1SMN1; SMN2POLBTP53 | |
| SCHEMBL6541161 | 0.89 | MAPT (0.45) | MAPTMAPK1SMN1; SMN2POLBTP53 | |
| SCHEMBL6677130 | 0.87 | LPAR1 (0.51) | LPAR1LPAR5HDAC3HDAC1HDAC2 | |
| SCHEMBL6540837 | 0.86 | POLB (0.53) | MAPTMAPK1SMN1; SMN2POLBTP53 | |
| SCHEMBL6800067 | 0.85 | LPAR1 (0.49) | LPAR1LPAR5MAPTCETPHDAC3 | |
| SCHEMBL6539988 | 0.85 | PPARA (0.47) | MAPTHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL6541216 | 0.84 | CYP4F2 (0.45) | MAPTMAPK1SMN1; SMN2POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | LPAR1 1110/4885LPAR5 1485/4885MAPT 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.